Praxis Precision Medicines enters $75M ATM equity offering with Jefferies LLC

Praxis Precision Medicines, Inc.

Up to $75M of common stock may be sold from time to time via Jefferies as sales agent.
Jefferies receives 3.0% commission on gross proceeds; company grants customary indemnification.
Sales will be made under existing effective shelf registration statement (S-3, Feb 2023).
Agreement can be terminated by either party upon 10 trading days' notice.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Praxis Precision Medicines, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75,000,000 (effective 2023-12-07).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $75,000,000
Effective: 2023-12-07

Exact text from the filing

On December 7, 2023, Praxis Precision Medicines, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with an aggregate offering price of up to $75,000,000, from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent.

View on SEC.gov

Browse all material agreements →

Praxis Precision Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-124348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.